Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05255354 · ClinicalTrials.gov registry record
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
A clinical trial of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, sponsored by Adaptive Biotechnologies.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT05255354 is a study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma that is actively recruiting participants, run by Adaptive Biotechnologies. The registered enrollment target is 300 participants, above the 216-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (39% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05255354, a study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, is actively recruiting participants, sponsored by Adaptive Biotechnologies.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ platform as specific quantification of residual DLBCL/FL/MCL and correlate its results with radiologic assessment of disease and clinical outcomes. Invesitgators predict there will be a strong correlation between ctDNA and PET/CT and dynamic changes in ctDNA will precede radiologic evidence of disease recurrence in patients following CAR therapy.
Conditions Studied
Interventions
- DEVICE ClonoSEQ
Study Locations (1)
California
- Stanford Cancer Center - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05255354
The ClinicalTrials.gov registry entry for NCT05255354 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 216-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (39% higher). The listed sponsor is Adaptive Biotechnologies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which ClonoSEQ is the first listed.
NCT05255354 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05255354 about?
NCT05255354 is a clinical study titled "Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy". In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ pl...
What is the current status of trial NCT05255354?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2022-06-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05255354 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma.
What interventions are being tested in trial NCT05255354?
The interventions under investigation include: ClonoSEQ (DEVICE).
Who is sponsoring clinical trial NCT05255354?
This trial is sponsored by Adaptive Biotechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05255354 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
RECRUITING
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.